News
06.29.20Podcast: Tim Germann our Chief Commercial Officer Discusses how Carterra has Become an Innovator and Driving Force in Therapeutic Antibody Discovery
News
06.18.20Nature Article: Speeding Antibody Screening for Drug Development
Advanced screening technology can dramatically accelerate the hunt for effective treatments for cancer, COVID-19 and more.
News
04.09.20Video: Carterra has been Selected by the Gates Foundation to Help Solve the COVID-19 Pandemic
News
03.31.20Carterra® Inc. Selected by the La Jolla Institute of Immunology to Provide Antibody Screening and Characterization for the Coronavirus Immunotherapy Consortium (CoVIC)
News
03.12.20Biocompare Article on How Epitope Binning Streamlines Discovery and Exploits Diversity
Epitope binning screens and characterizes antibodies in one step. Studying kinetics, affinity, and epitope relationships in high throughput allows characterization of antibody libraries generated against a specific antigen through B cell cloning, phage display, or hybridoma technologies.
News
01.14.20Platform for Next Generation Antibody Discovery
Additional Resources Will Support New Product Development and Global Expansion
News
10.17.192019 Carterra Symposia
View the slides of the presentations from the therapeutic antibody revolution in the post genomics era symposia.
News
09.05.19Bristol-Myers Squibb, Boehringer Ingelheim and Other Biotechnology Companies to Present Use of Carterra’s Next Generation Antibody Screening Technology at Symposia Across the US and Europe
News
08.14.19Rapid Adoption of Carterra’s LSA® Instrument Drives European Expansion
Carterra® Inc., the world leader in high-throughput antibody screening and characterization, announced today that they have opened a Customer Experience Center (CEC) and office in Munich, Germany. Rapid European adoption of Carterra’s platform has fueled the need for the new office.
News
05.15.19GEN Article: A Therapeutic Antibody Characterization Trinity Accelerates Drug Development
The three core applications of high throughput SPR that form the antibody characterization trinity are capture kinetics, epitope binning, and epitope mapping. Together, they provide a comprehensive characterization of antibody libraries with minimal sample consumption, enabling more confident decisions to be made earlier and obviating the need for preliminary ELISA screening.